Pfizer’s New York headquarters.
Pfizer and Germany’s BioNTech announced on Wednesday that they will develop a potential mRNA-based vaccine to prevent viral shingles. This is the third collaboration after their successful COVID-19 vaccine.
Pfizer cooperated with BioNTech to develop a flu vaccine in 2018, and again in 2020 to develop a COVID-19 vaccine, which has been used globally and has brought billions of dollars in sales to the company.
The two companies plan to start clinical trials of the shingles vaccine in the second half of 2022. The vaccine will combine antigen technology approved by Pfizer scientists with BioNTech’s mRNA platform technology.
Shingles, also called shingles, usually occurs in older people who have chickenpox or varicella-zoster virus when they are young.
Its hallmark is a painful rash, which in most cases disappears within a month. However, in some cases, this can cause nerve pain. This pain can last longer. With cooperation, BioNTech will receive an advance payment of US$225 million and is eligible for future regulatory and commercial payments of up to US$200 million. BioNTech will pay US$25 million for Pfizer’s proprietary antigen technology.
go to see more here in tech news